abstract：:Abacavir is an effective antiretroviral drug used to treat HIV-1 infection. Approximately 5% of patients treated with abacavir develop a hypersensitivity reaction that requires discontinuation of the drug. In an initial pharmacogenetic study conducted in a predominantly White male population, multiple markers in the h...

journal_title：Pharmacogenomics

authors： Hughes AR,Mosteller M,Bansal AT,Davies K,Haneline SA,Lai EH,Nangle K,Scott T,Spreen WR,Warren LL,Roses AD,CNA30027 Study Team.,CNA30032 Study Team.

更新日期：2004-03-01 00:00:00

abstract：:The number of reports investigating disease susceptibility based on the carriage of low-penetrance, high-frequency polymorphisms has steadily increased over the last years. Evidence based on meta-analyses of individual case-control studies is accumulating, defining specific individual variations in disease susceptibil...

journal_title：Pharmacogenomics

authors： Tempfer CB,Schneeberger C,Huber JC

更新日期：2004-01-01 00:00:00

abstract：:Pharmacogenomic analyses will become crucial to predict patients' toxicity to treatment and will also help to predict the tumor response. Processes of drug metabolism, drug efflux, DNA-repair and characteristics of drug targets are critical checkpoints of drug efficacy. These crucial pathways for drug action have been...

journal_title：Pharmacogenomics

authors： Stoehlmacher J,Goekkurt E,Lenz HJ

更新日期：2003-11-01 00:00:00

abstract：:The polymorphism CYP1A2*1F of the cytochrome 1A2 gene affects the inducibility of this cytochrome, which is involved in the metabolism of many commonly used drugs. We developed a rapid-cycle polymerase chain reaction (PCR) and fluorescent probe melting curve analysis on the LightCycler instrument for identification of...

journal_title：Pharmacogenomics

authors： Popp J,Messner B,Steimer W

更新日期：2003-09-01 00:00:00

abstract：:The multi-drug resistant transporter MDR1/P-glycoprotein, the gene product of MDR1, is a glycosylated membrane protein of 170 kDa, belonging to the ATP-binding cassette (ABC) superfamily of membrane transporters. MDR1 was originally isolated from resistant tumor cells as part of the mechanism of multi-drug resistance,...

journal_title：Pharmacogenomics

authors： Sakaeda T,Nakamura T,Okumura K

更新日期：2003-07-01 00:00:00

abstract：:Psoriasis vulgaris is one of the most prevalent T cell-mediated inflammatory diseases in humans. It is multifactorial in origin and shows polygenic inheritance. Systemic immunosuppressive therapies play an important role in management of severe disease cases but are associated with variable response and toxicity. With...

journal_title：Pharmacogenomics

authors： Ameen M

更新日期：2003-05-01 00:00:00

abstract：:The human oral cavity represents a complex ecology of approximately 500 microbial species existing as commensals, and interacting with human/host factors. Perturbation of this ecosystem can lead to diseases of the oral cavity. The oral cavity also acts as a mirror of complex systemic diseases. Unique challenges and op...

journal_title：Pharmacogenomics

authors： Slavkin HC

更新日期：2003-03-01 00:00:00

abstract：:DxS is a pharmacogenomics business operating at the interface between genetic diagnostics and the pharmaceutical industry. The company strategy is to enable pharmacogenomics by the provision of genetic analysis services to the healthcare sector. The services provide support for drug discovery, drug development and als...

journal_title：Pharmacogenomics

authors： Little S

更新日期：2003-01-01 00:00:00

abstract：:Pharmacogenomics seeks to understand the genetic basis of interindividual differences in drug disposition and effects. Differential drug response is likely to most often be a complex trait, in which multiple genes contribute with varying strengths to the therapeutic phenotype. Due to technical and economic limitations...

journal_title：Pharmacogenomics

authors： Watters JW,McLeod HL

更新日期：2002-11-01 00:00:00

abstract：:The value of high-throughput genomic research is dramatically enhanced by association with key patient data. These data are generally available but of disparate quality and not typically directly associated. A system that could bring these disparate data sources into a common resource connected with functional genomic...

journal_title：Pharmacogenomics

authors： Thallinger GG,Trajanoski S,Stocker G,Trajanoski Z

更新日期：2002-09-01 00:00:00

abstract：:The first observations of inherited differences in drug effects in the 1950s led to the recognition of a genetic basis for drug response. With the development of genetics and molecular biology, it became clear that certain drug responses could be associated with specific genetic variations or polymorphisms. There are ...

journal_title：Pharmacogenomics

authors： Ferentz AE

更新日期：2002-07-01 00:00:00

abstract：:The emergence of antibiotic resistance and multi-drug resistance in bacterial pathogens underscores the need for the development of novel classes of antibiotics. The availability of complete genome sequence data from many important human pathogens provides a wealth of fundamental information. This allows us to define ...

journal_title：Pharmacogenomics

authors： Ji Y

更新日期：2002-05-01 00:00:00

abstract：:Genetic variation in the beta 2-adrenoceptor and its associated proteins is common and therefore potentially relevant to the clinician. Several functional SNPs have been described but in vitro studies have yielded inconsistent results. Confounding due to the variable presence of other polymorphic alleles may be the ex...

journal_title：Pharmacogenomics

authors： Taylor DR,Kennedy MA

更新日期：2002-03-01 00:00:00

abstract：:Arylamine N-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to arylhydrazines and to arylamine drugs and carcinogens or to their N-hydroxylated metabolites. NAT plays an important role in detoxification and metabolic activation of xenobiotics and was first identified as the enzyme re...

journal_title：Pharmacogenomics

authors： Pompeo F,Brooke E,Kawamura A,Mushtaq A,Sim E

更新日期：2002-01-01 00:00:00

abstract：:Discovery Partners International (Nasdaq: DPII) is a leader in collaborative drug discovery. DPI's integrated discovery framework encompasses a broad spectrum of capabilities in chemistry, biology, informatics, computational modeling and synthesis automation. DPI's approach to drug discovery places a heavy emphasis on...

journal_title：Pharmacogenomics

authors： Herd C

更新日期：2002-01-01 00:00:00

abstract：:The completion of the first draft of the human genome sequence has revived the old notion that there is no one-to-one mapping between genotype and phenotype. It is now becoming clear that to elucidate the fundamental principles that govern how genomic information translates into organismal complexity, we must overcome...

journal_title：Pharmacogenomics

authors： Huang S

更新日期：2001-08-01 00:00:00

abstract：:The response to lipid-lowering drugs is modified by a number of factors like age, gender, concomitant disease and genetic determinants. Even within homogenous groups of patients, individual responses vary greatly. Until now, no clinical or biochemical parameter exists which predicts whether a subject will respond well...

journal_title：Pharmacogenomics

authors： Hoffmann MM,Winkelmann BR,Wieland H,März W

更新日期：2001-05-01 00:00:00

abstract：:Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarray technology covered the latest advances in this technology and applications in life sciences. Highlights of the meetings are reported briefly with emphasis on applications in genomics, drug discovery and molecular diagnostics. Ther...

journal_title：Pharmacogenomics

authors： Jain KK

更新日期：2001-02-01 00:00:00

abstract：:A DNA microarray system is usually comprised of DNA probes formatted on a microscale on a glass surface (chip), plus the instruments needed to handle samples (automated robotics), to read the reporter molecules (scanners) and analyse the data (bioinformatic tools). Biochips are formed by in situ (on chip) synthesis of...

journal_title：Pharmacogenomics

authors： Jain KK

更新日期：2000-08-01 00:00:00

abstract：:RNA splicing is a tightly regulated process. It is essential for gene expression and, therefore, intervenes in every biological phenomenon in mammals. RNA splicing regulation is cell type-specific in such a way that a cellular situation can be characterised by its repertoire of spliced events, the spliceome. Compariso...

journal_title：Pharmacogenomics

authors： Schweighoffer F,Ait-Ikhlef A,Resink AL,Brinkman B,Melle-Milovanovic D,Laurent-Puig P,Kearsey J,Bracco L

更新日期：2000-05-01 00:00:00

abstract：:High-throughput genotyping approaches are being developed to meet the demands of pharmacogenomnics, where numerous individuals are studied with thousands of single nucleotide polymorphism (SNP) markers. All non-gel-based genotyping approaches achieve allelic discrimination by one of four mechanisms: allele-specific hy...

journal_title：Pharmacogenomics

authors： Kwok PY

更新日期：2000-02-01 00:00:00